NASPI: N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization
N-Acetylcysteine vs. Ascorbic Acid for Prevention of Contrast Induced Nephropathy in Renal Insufficiency Undergoing Coronary Catheterization: NASPI Study-A Randomized Controlled Trial
Sponsor: Seoul National University Hospital
Listed as NCT00356954, this PHASE4 trial focuses on Kidney Failure and remains completed. Sponsored by Seoul National University Hospital, it has been updated 6 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Seoul National University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .